PharmChem, Inc.
Other OTCTotal Valuation
PharmChem, Inc. carries a market capitalization of 21.95M, placing it among publicly traded companies globally. Its enterprise value stands at 5.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21.95M |
| Enterprise Value | 5.73M |
Share Statistics
PharmChem, Inc. currently has 5.85M shares outstanding.
| Shares Outstanding | 5.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
PharmChem, Inc. trades at a trailing price-to-earnings ratio of 0.18. The price-to-sales ratio is 0.09, and the price-to-book ratio stands at -0.24.
| PE Ratio | 0.18 |
| PS Ratio | 0.09 |
| PB Ratio | -0.24 |
| P/TBV Ratio | 0.29 |
| P/FCF Ratio | -25.95 |
| P/OCF Ratio | -3.62 |
Enterprise Valuation
On an enterprise value basis, PharmChem, Inc. trades at an EV/EBITDA multiple of 5.66 and an EV/FCF ratio of 10.24.
| EV / Sales | 0.21 |
| EV / EBITDA | 5.66 |
| EV / EBIT | N/A |
| EV / FCF | 10.24 |
Financial Position
PharmChem, Inc. maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.23 |
| Quick Ratio | 1.01 |
| Debt / Equity | 51.28 |
| Debt / EBITDA | 4.75 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -4.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 18.59 |
Stock Price Statistics
PharmChem, Inc.'s stock has gained approximately 11.27596% over the past 52 weeks. The 50-day moving average sits at 3.76, while the 200-day moving average is 3.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | 11.27596% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 3.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, PharmChem, Inc. generated 27.62M in revenue and converted that into -990,000.00 in net income, yielding earnings per share of -0.17. EBITDA reached 1.01M, while operating income came in at -1.12M.
| Revenue | 27.62M |
| Gross Profit | 6.36M |
| Operating Income | -1.12M |
| Pretax Income | -990,000.00 |
| Net Income | -990,000.00 |
| EBITDA | 1.01M |
| EBIT | -1.12M |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
PharmChem, Inc. holds 1.58M in cash and equivalents against 4.80M in total debt, resulting in a net debt position of 3.22M. Total book value stands at -10.27M, with working capital of 1.28M providing operational flexibility.
| Cash & Cash Equivalents | 1.58M |
| Total Debt | 4.80M |
| Net Debt | 3.22M |
| Equity (Book Value) | -10.27M |
| Book Value Per Share | -1.75 |
| Working Capital | 1.28M |
Cash Flow
PharmChem, Inc. produced -693,000.00 in operating cash flow over the past twelve months. After subtracting -596,000.00 in capital expenditures, free cash flow totaled -1.29M - equivalent to -0.22 per share.
| Operating Cash Flow | -693,000.00 |
| Capital Expenditures | -596,000.00 |
| Free Cash Flow | -1.29M |
| FCF Per Share | -0.22 |
Margins
PharmChem, Inc. operates with a gross margin of 23.04, reflecting its pricing power and cost economics. The operating margin of -4.05 and net profit margin of -3.58 provide insight into operational efficiency.
| Gross Margin | 23.04 |
| Operating Margin | -4.05 |
| Pretax Margin | -3.58 |
| Profit Margin | -3.58 |
| EBITDA Margin | 3.66 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 71.21 |
| FCF Yield | -3.85 |
Stock Splits
PharmChem, Inc.'s most recent stock split took place on November 5, 2020 with a 6:1 split ratio.
| Last Split Date | 11/5/2020 |
| Split Ratio | 6:1 |
Scores
PharmChem, Inc. posts an Altman Z-Score of 0.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.79 |